Literature DB >> 18406256

TSH Receptor Mutations and Thyroid Disease.

L Duprez1, J Parma, J Van Sande, P Rodien, J E Dumont, G Vassart, M Abramowicz.   

Abstract

Mutations of the thyrotropin receptor (TSHr) can be loss of function or gain of function. Loss-of-function mutations can affect a variety of loci in the TSHr gene. Their most common manifestation is resistance to TSH; they may also be the cause of a subset of cases of congenital hypothyroidism. Gain-of-function mutations are of greater theoretical interest. Somatic mutations constitutively activating the TSHr are the major cause of benign toxic thyroid adenomas, and of some cases of multinodular goiters. They underlie hereditary toxic thyroid hyperplasia, and have been found in cases of sporadic congenital non-autoimmune hyperthyroidism. A role for TSHr polymorphisms in Graves' disease has not been documented.

Entities:  

Year:  1998        PMID: 18406256     DOI: 10.1016/s1043-2760(98)00036-8

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  15 in total

1.  Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess.

Authors:  Hellevi Peltoketo; Leena Strauss; Riikka Karjalainen; Meilin Zhang; Gordon W Stamp; Deborah L Segaloff; Matti Poutanen; Ilpo T Huhtaniemi
Journal:  Endocrinology       Date:  2010-02-19       Impact factor: 4.736

2.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

5.  New small molecule agonists to the thyrotropin receptor.

Authors:  Rauf Latif; M Rejwan Ali; Risheng Ma; Martine David; Syed A Morshed; Michael Ohlmeyer; Dan P Felsenfeld; Zerlina Lau; Mihaly Mezei; Terry F Davies
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

6.  Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex.

Authors:  M Casey; C J Vaughan; J He; C J Hatcher; J M Winter; S Weremowicz; K Montgomery; R Kucherlapati; C C Morton; C T Basson
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 7.  Update in TSH receptor agonists and antagonists.

Authors:  Marvin C Gershengorn; Susanne Neumann
Journal:  J Clin Endocrinol Metab       Date:  2012-09-27       Impact factor: 5.958

8.  Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation.

Authors:  F Arturi; E Chiefari; S Tumino; D Russo; S Squatrito; G Chazenbalk; L Persani; B Rapoport; S Filetti
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

9.  A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

10.  The W520X mutation in the TSHR gene brings on subclinical hypothyroidism through an haploinsufficiency mechanism.

Authors:  S Moia; M Godi; G E Walker; M Roccio; P Agretti; M Tonacchera; R Berardi; S Bellone; F Prodam; M Giordano; G Bona
Journal:  J Endocrinol Invest       Date:  2013-04-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.